Are 25 antibodies better than 1?

Abstract

In this issue of Blood, Robak et al present data suggesting that rozrolimupab, a first-in-class mixture of 25 recombinant monoclonal IgG1 antibodies against RhD, has efficacy similar to plasma-derived anti-RhD in the treatment of immune thrombocytopenia.